TRAIL, Human, Recombinant <Apo2L>

• 商品コード：310-04
• メーカー：PEP
• 包装：1mg
• 本製品は製品内容等が変更されました 変更先製品

マイリストに追加 マイリストに追加済

• No.： 1
• 文献情報：
  Kilic M et al. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007 Mar;26(14):2027-38
  Kilic M et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 2
• 文献情報：
  Grabarczyk P et al. Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene 2007 May;26(26):3797-810
  Grabarczyk P et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 3
• 文献情報：
  Li H et al. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J. Biol. Chem. 2007 Feb;282(7):4943-50
  Li H et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 4
• 文献情報：
  Mulherkar N et al. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. J. Biol. Chem. 2007 Apr;282(16):11715-21
  Mulherkar N et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 5
• 文献情報：
  Keogh RJ et al. Fetal-derived trophoblast use the apoptotic cytokine tumor necrosis factor-alpha-related apoptosis-inducing ligand to induce smooth muscle cell death. Circ. Res. 2007 Mar;100(6):834-41
  Keogh RJ et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 6
• 文献情報：
  Johnson AL et al. Tumor necrosis factor-related apoptosis inducing ligand expression and activity in hen granulosa cells. Reproduction 2007 Mar;133(3):609-16
  Johnson AL et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 7
• 文献情報：
  Wei J et al. Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells. Cancer Gene Ther. 2007 Jul;14(7):640-51
  Wei J et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 8
• 文献情報：
  Qiu Y et al. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res. 2007 May;67(10):4973-80
  Qiu Y et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 9
• 文献情報：
  Liu X et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 20
  Liu X et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 10
• 文献情報：
  Fu NY et al. Inhibition of ubiquitin-mediated degradation of MOAP-1 by apoptotic stimuli promotes Bax function in mitochondria. Proc. Natl. Acad. Sci. U.S.A. 2007 Jun;104(24):10051-6
  Fu NY et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 11
• 文献情報：
  Song JH et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res. 2007 Jul;67(14):6946-55
  Song JH et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 12
• 文献情報：
  Wang P et al. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell. Signal. 2007 Nov;19(11):2237-46
  Wang P et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 13
• 文献情報：
  Cheriyath V et al. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J. Clin. Invest. 2007 Oct;117(10):3107-17
  Cheriyath V et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 14
• 文献情報：
  Baritaki S et al. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J. Immunol. 2007 Oct;179(8):5441-53
  Baritaki S et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 15
• 文献情報：
  Chakravarti A et al. Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Lab. Invest. 2008 Feb;88(2):171-84
  Chakravarti A et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 16
• 文献情報：
  Goda AE et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008 May;27(24):3435-45
  Goda AE et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 17
• 文献情報：
  Toscano F et al. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene 2008 Jul;27(30):4161-71
  Toscano F et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 18
• 文献情報：
  Baritaki S et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J. Immunol. 2008 May;180(9):6199-210
  Baritaki S et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 19
• 文献情報：
  Ashley DM et al. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br. J. Cancer 2008 Jul;99(2):294-304
  Ashley DM et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 20
• 文献情報：
  Dida F et al. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. Exp. Hematol. 2008 Oct;36(10):1343-53
  Dida F et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 21
• 文献情報：
  Song JH et al. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem. 2008 Sep;283(36):25003-13
  Song JH et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 22
• 文献情報：
  Fakler M et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009 Feb;113(8):1710-22
  Fakler M et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 23
• 文献情報：
  Sun B et al. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments. J. Urol. 2009 Mar;181(3):1361-71
  Sun B et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 24
• 文献情報：
  Lundqvist A et al. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009 Jun;113(24):6120-7
  Lundqvist A et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 25
• 文献情報：
  Xu L et al. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett. 2009 Mar;583(5):943-8
  Xu L et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 26
• 文献情報：
  Autefage H et al. Lysosomal serine protease CLN2 regulates tumor necrosis factor-alpha-mediated apoptosis in a Bid-dependent manner. J. Biol. Chem. 2009 Apr;284(17):11507-16
  Autefage H et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 27
• 文献情報：
  Szliszka E et al. Dietary Flavonoids Sensitize HeLa Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). Int J Mol Sci 2008 Jan;9(1):56-64
  Szliszka E et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 28
• 文献情報：
  Wang C et al. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J.
  Wang C et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 29
• 文献情報：
  Morioka S et al. TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP. Oncogene 2009 Jun;28(23):2257-65
  Morioka S et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 30
• 文献情報：
  Menon LG et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009 Sep;27(9):2320-30
  Menon LG et al
  2009/01/01
  
• 備考：
  
• 参照：